- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.01. | Femasys Inc.: Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed for Female Infertility Treatment | 2 | GlobeNewswire (USA) | ||
| 27.11.24 | The Latest Analyst Ratings For Femasys | 4 | Benzinga.com | ||
| 26.11.24 | Femasys Inc.: Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed Infertility Treatment | 89 | GlobeNewswire (Europe) | ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office... ► Artikel lesen | |
| 12.11.24 | Femasys GAAP EPS of -$0.24, revenue of $554.91M | 1 | Seeking Alpha | ||
| FEMASYS Aktie jetzt für 0€ handeln | |||||
| 12.11.24 | Femasys Inc.: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update | 81 | GlobeNewswire (Europe) | ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office... ► Artikel lesen | |
| 01.11.24 | Femasys secures new patent for FemBloc birth control | 2 | Investing.com | ||
| 01.11.24 | Femasys Inc.: Femasys Announces Issued U.S. Patent Covering FemBloc Device for Female Permanent Birth Control | 1 | GlobeNewswire (USA) | ||
| 30.10.24 | Femasys Inc.: Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed | 1 | GlobeNewswire (USA) | ||
| 29.10.24 | FEMASYS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 10.10.24 | Femasys Inc.: Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program | 1 | GlobeNewswire (USA) | ||
| 02.10.24 | Femasys Inc.: Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments | 1 | GlobeNewswire (USA) | ||
| 18.09.24 | Femasys Inc.: Femasys Announces Infertility Clinic Customers from Coast to Coast | 4 | GlobeNewswire (USA) | ||
| 12.09.24 | H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution | 1 | Investing.com | ||
| 12.09.24 | Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 1 | Benzinga.com | ||
| 11.09.24 | Femasys secures partnerships for commercialization of Femaseed and FemVue | 1 | Seeking Alpha | ||
| 11.09.24 | Femasys Inc.: Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market | 1 | GlobeNewswire (USA) | ||
| 10.09.24 | Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device | 1 | Zacks | ||
| 09.09.24 | FDA clears Femasys' FemChec diagnostic device | 1 | MassDevice | ||
| 09.09.24 | Femasys Receives 510(k) Clearance From FDA To Market FemChec For Fallopian Tube Diagnosis | - | RTTNews | ||
| 09.09.24 | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 585,00 | -0,24 % | Intuitive Surgical: Dr. Robot ist nicht zu stoppen - neues Rekordhoch | Der Weltmarktführer für Roboter-assistierte Technologien hat am Mittwoch vorläufige Zahlen für das vierte Quartal respektive Gesamtjahr 2024 vorgelegt. Und diese können sich sehen lassen. Die Aktie... ► Artikel lesen | |
| ROKU | 77,68 | +1,62 % | Roku (NASDAQ:ROKU) Trading Down 0.8% - What's Next? | ||
| ATOSSA THERAPEUTICS | 0,932 | +0,65 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 | SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| QUIDELORTHO | 42,200 | -1,40 % | QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024 | SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,857 | +0,53 % | Tempest Therapeutics: Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) | BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| CENTENE | 62,04 | +1,65 % | Greenlight Capital Added Centene (CNC) on Dip | ||
| VERU | 1,174 | +16,93 % | Stock Traders Purchase Large Volume of Veru Call Options (NASDAQ:VERU) | ||
| NANO-X IMAGING | 8,705 | -3,06 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen | |
| FULGENT GENETICS | 16,100 | -1,23 % | Fulgent Reports Third Quarter 2024 Financial Results | EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic... ► Artikel lesen | |
| LANTHEUS | 92,12 | +0,61 % | Lantheus To Buy Life Molecular Imaging For Upfront Payment Of $350 Million | ||
| PERSPECTIVE THERAPEUTICS | 3,260 | +2,52 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 | ||
| AMN HEALTHCARE SERVICES | 25,400 | +2,42 % | Bear of the Day: AMN Healthcare Services (AMN) | ||
| OMNICELL | 40,400 | -1,46 % | Omnicell Announces Third Quarter 2024 Results | FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today... ► Artikel lesen | |
| ALPHATEC | 10,700 | 0,00 % | Alphatec (NASDAQ:ATEC) Price Target Raised to $21.00 at Barclays |
FEMASYS INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 1,140 Euro und damit +0,44 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.
